Atara Biotherapeutics, Inc.
ATRANasdaqCIK 1604464HealthcareFiscal year ends Dec 31
Reports and events: 227 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1216:15 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-346885 |
| 2026-08-1216:10 ET | 8-K | 2.02 Results of operations | 0001193125-26-346857 |
| 2026-07-2420:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-26-086728 |
| 2026-06-2616:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-285498 |
| 2026-06-1216:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001213900-26-068264 |
| 2026-05-1421:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-26-061506 |
| 2026-05-1216:15 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-219482 |
| 2026-05-1216:10 ET | 8-K | 9.01 Financial statements and exhibits | 0001193125-26-219420 |
| 2026-05-1118:49 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001193125-26-217389 |
| 2026-05-0708:10 ET | 8-K | 8.01 Other events | 0001193125-26-210413 |
| 2026-05-0116:05 ET | 8-K | 3.01 Delisting notice | 0001193125-26-201397 |
| 2026-04-2416:15 ET | DEF 14A | Proxy statementPeriod 2026-04-24 | 0001193125-26-177285 |
| 2026-03-1616:15 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-108361 |
| 2026-03-1616:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-108344 |
| 2026-03-1208:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-103127 |
| 2026-03-0308:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-086793 |
| 2026-02-2308:29 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-062534 |
| 2026-01-1421:20 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001193125-26-013362 |
| 2026-01-1216:00 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-010342 |
| 2026-01-0216:01 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-000907 |
| 2025-11-1416:19 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-25-112574 |
| 2025-11-1209:10 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-276219 |
| 2025-11-1209:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-276209 |
| 2025-10-0717:32 ET | 8-K | 2.05 Exit or disposal costs | 0001193125-25-232117 |
| 2025-09-0418:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-25-112898 |
| 2025-08-1920:15 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000950170-25-110311 |
| 2025-08-1116:10 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-106550 |
| 2025-08-1116:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-106533 |
| 2025-07-1416:03 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-158719 |
| 2025-06-1116:15 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-139150 |
| 2025-05-2316:05 ET | SCHEDULE 13D | Ownership report, active investor | 0001104659-25-052422 |
| 2025-05-2118:00 ET | SCHEDULE 13D | Ownership report, active investor | 0000950170-25-075903 |
| 2025-05-1618:28 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-25-050119 |
| 2025-05-1617:26 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-121824 |
| 2025-05-1508:45 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-072040 |
| 2025-05-1508:41 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-120345 |
| 2025-05-1216:10 ET | 8-K | 2.05 Exit or disposal costs | 0000950170-25-069198 |
| 2025-05-0616:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-113811 |
| 2025-04-2816:15 ET | DEF 14A | Proxy statementPeriod 2025-06-10 | 0000950170-25-059322 |
| 2025-04-0416:10 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-25-051121 |
| 2025-03-3116:28 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-068789 |
| 2025-03-0716:10 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-035507 |
| 2025-03-0716:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-035482 |
| 2025-03-0316:05 ET | 8-K | 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0000950170-25-030832 |
| 2025-01-2716:30 ET | 8-K | 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0000950170-25-009225 |
| 2025-01-2107:36 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-006992 |
| 2025-01-1616:05 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-006191 |
| 2024-12-2316:00 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-284167 |
| 2024-11-1216:10 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125389 |
| 2024-11-1216:05 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-125334 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.